Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.51 |
| ▸ | HRH2 | P25021 | 4/20 | 0.51 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367453 | 1.00 | RAB9A (0.65) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL1714789 | 1.00 | RAB9A (0.65) | RAB9AGAANPC1LMNATP53 | |
| Hydrochloric Acid SCHEMBL1715673 | 0.98 | RAB9A (0.63) | RAB9AGAANPC1LMNATP53 | |
| Hydrochloric Acid SCHEMBL1715672 | 0.98 | RAB9A (0.63) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL7300668 | 0.94 | RAB9A (0.62) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL7292450 | 0.93 | HRH3 (0.61) | RAB9AGAAHRH3KDM4EMAOB | |
| SCHEMBL7293962 | 0.90 | HRH3 (0.62) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL13403634 | 0.87 | GAA (0.53) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL2338934 | 0.87 | GAA (0.53) | RAB9AGAANPC1LMNATP53 | |
| SCHEMBL2338942 | 0.87 | GAA (0.53) | RAB9AGAANPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | RAB9A 623/4885GAA 1368/4885NPC1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.